{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:48:10Z","timestamp":1783687690050,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000811","name":"European Institute of Innovation and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000811","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"Narodowe Centrum Bada\u0144 i Rozwoju","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.taap.2020.115139","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T04:03:19Z","timestamp":1594958599000},"page":"115139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL"],"prefix":"10.1016","volume":"403","author":[{"given":"Ida","family":"Franiak-Pietryga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ziemba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Sikorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Jander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Kuncman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Danilewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Appelhans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemyslaw","family":"Lewkowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Ostrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bryszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Borowiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2020.115139_bb0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/DDDT.S104869","article-title":"Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy","volume":"11","author":"Al-Sawaf","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.taap.2020.115139_bb0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1021\/acs.bioconjchem.6b00635","article-title":"Interactions of nitroxide-conjugated and non-conjugated glycodendrimers with normal and cancer cells and biocompatibility studies","volume":"28","author":"Andreozzi","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.taap.2020.115139_bb0015","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1098\/rspa.2009.0107","article-title":"Dense-shell glycodendrimers: UV\/Vis and electron paramagnetic resonance study of metal ion complexation","volume":"466","author":"Appelhans","year":"2010","journal-title":"Proc R. Soc. Am."},{"key":"10.1016\/j.taap.2020.115139_bb0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0609.2011.01626.x","article-title":"Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD\/SCID xenograft model","volume":"87","author":"Aydin","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.taap.2020.115139_bb0025","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1182\/blood-2010-12-324210","article-title":"A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease","volume":"117","author":"Bagnara","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.taap.2020.115139_bb0030","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood-2009-05-223586","article-title":"A novel Rag2\u2212\/\u2212gammac\u2212\/\u2212\u2212xenograft model of human CLL","volume":"115","author":"Bertilaccio","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.taap.2020.115139_bb0035","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/anie.199313081","article-title":"Poly(propylene imine) Dendrimers: large-scale synthesis by Hetereogeneously catalyzed hydrogenations","volume":"32","author":"de Brabander-van den Berg","year":"1993","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.taap.2020.115139_bb0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.gde.2013.11.008","article-title":"The importance of animal models in tumor immunity and immunotherapy","volume":"24","author":"Budhu","year":"2014","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.taap.2020.115139_bb0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CMAR.S34273","article-title":"Treatment challenges in the management of relapsed or refractory non-Hodgkin\u2019s lymphoma - novel and emerging therapies","volume":"5","author":"Chao","year":"2013","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.taap.2020.115139_bb0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s13105-012-0158-y","article-title":"Modulation of biogenic amines content by poly(propylene imine) dendrimers in rats","volume":"68","author":"Ciepluch","year":"2012","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.taap.2020.115139_bb0055","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/clpt.2013.117","article-title":"Clinical approval success rates for investigational cancer drugs","volume":"94","author":"DiMasi","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2020.115139_bb0060","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.1158\/0008-5472.CAN-07-1198","article-title":"A novel nonobese diabetic\/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease","volume":"67","author":"Durig","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2020.115139_bb0100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1871520616666160622092947","article-title":"Glycodendrimer PPI as a potential drug in chronic lymphocytic leukaemia. The influence of glycodendrimer on apoptosis in in vitro B-CLL cells defined by microarrays","volume":"17","author":"Franiak-Pietryga","year":"2017","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.taap.2020.115139_bb0065","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1021\/mp400142p","article-title":"The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI","volume":"10","author":"Franiak-Pietryga","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.taap.2020.115139_bb0070","first-page":"223","article-title":"Potential genetic agent BFL1 for targeted therapy in chronic lymphocytic leukemia","volume":"11","author":"Franiak-Pietryga","year":"2015","journal-title":"Eur. Sci. J."},{"key":"10.1016\/j.taap.2020.115139_bb0075","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijbiomac.2016.03.021","article-title":"Dendrimer-based nanoparticles for potential personalized therapy in chronic lymphocytic leukemia: targeting the BCR-signaling pathway","volume":"88","author":"Franiak-Pietryga","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.taap.2020.115139_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.201700130","article-title":"Blockage of Wnt\/beta-catenin signaling by nanoparticles reduces survival and proliferation of CLL cells in vitro-preliminary study","volume":"17","author":"Franiak-Pietryga","year":"2017","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.taap.2020.115139_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.201600169","article-title":"PPI-G4 glycodendrimers upregulate TRAIL-induced apoptosis in chronic lymphocytic leukemia cells","volume":"17","author":"Franiak-Pietryga","year":"2017","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.taap.2020.115139_bb0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.taap.2018.08.007","article-title":"Affecting NF-\u03baB cell signaling pathway in chronic lymphocytic leukemia by dendrimers-based nanoparticles","volume":"357","author":"Franiak-Pietryga","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2020.115139_bb0090","article-title":"Effects of Maltotriose-modified PPI Dendrimers on the subcutaneous MEC-1 Xenograft tumor model of human CLL in NSG mice","author":"Franiak-Pietryga","year":"2019","journal-title":"Mendeley"},{"key":"10.1016\/j.taap.2020.115139_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejpb.2016.12.030","article-title":"Dendrimers as nanocarriers for nucleoside analogues","volume":"114","author":"Gorzkiewicz","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.taap.2020.115139_bb0110","doi-asserted-by":"crossref","DOI":"10.4137\/CIN.S13974","article-title":"Growth rate analysis and efficient experimental design for tumor xenograft studies","author":"Hather","year":"2014","journal-title":"Cancer Inform."},{"key":"10.1016\/j.taap.2020.115139_bb0115","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.3109\/10428194.2013.856008","article-title":"Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma","volume":"55","author":"Herting","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.taap.2020.115139_bb0120","series-title":"Targeted Therapy in Translational Cancer Research","first-page":"130","article-title":"Chronic lymphocytic Leukemia","author":"Jain","year":"2015"},{"issue":"2012","key":"10.1016\/j.taap.2020.115139_bb0125","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1039\/C1NJ20444K","article-title":"The biodistribution of maltotriose modified poly(propylene imine) (PPI) dendrimers conjugated with fluorescein \u2014 proofs of crossing blood brain barrier","volume":"36","author":"Janaszewska","year":"2012","journal-title":"New J. Chem."},{"key":"10.1016\/j.taap.2020.115139_bb0130","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","article-title":"Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia","volume":"108","author":"Johnson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.taap.2020.115139_bb0135","series-title":"Pharmacology in Drug Discovery and Development","first-page":"193","article-title":"Pharmacokinetics II","author":"Kenakin","year":"2017"},{"key":"10.1016\/j.taap.2020.115139_bb0140","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/cncr.26360","article-title":"Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737","volume":"118","author":"Kojima","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.taap.2020.115139_bb0145","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.leukres.2005.04.017","article-title":"Establishment of a novel human B-CLL-like xenograft model in nude mouse","volume":"29","author":"Loisel","year":"2005","journal-title":"Leuk. Res."},{"key":"10.1016\/j.taap.2020.115139_bb0150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.drudis.2014.12.006","article-title":"How many times should we screen a chemical library to discover an anticancer drug?","volume":"20","author":"L\u00f3pez-L\u00e1zaro","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.taap.2020.115139_bb0155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/wnan.1315","article-title":"Nanomedical engineering: shaping future nanomedicines","volume":"7","author":"Luo","year":"2015","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.taap.2020.115139_bb0160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0168-3659(99)00246-1","article-title":"Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of125I-labelled polyamidoamine dendrimers in vivo","volume":"65","author":"Malik","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.taap.2020.115139_bb0165","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejmech.2017.03.035","article-title":"Anticancer copper(II) phosphorus dendrimers are potent proapoptotic Bax activators","volume":"132","author":"Mignani","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.taap.2020.115139_bb0170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1039\/B901839P","article-title":"Biomedical applications of dendrimers: a tutorial","volume":"40","author":"Mintzer","year":"2011","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.taap.2020.115139_bb0175","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/jbio.200910002","article-title":"Selective targeting of green fluorescent nanodiamond conjugates to mitochondria in HeLa cells","volume":"2","author":"Mkandawire","year":"2009","journal-title":"J. Biophotonics"},{"key":"10.1016\/j.taap.2020.115139_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2017.11.006","article-title":"Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection\/infusion reactions","author":"Moghimi","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.taap.2020.115139_bb0185","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejpb.2008.09.023","article-title":"Dendrimers as versatile platform in drug delivery applications","volume":"71","author":"Svenson","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.taap.2020.115139_bb0190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1021\/cr068212n","article-title":"Dendrimers in oncology: an expanding horizon","volume":"109","author":"Tekade","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.taap.2020.115139_bb0195","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","author":"Thompson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.taap.2020.115139_bb0200","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.taap.2020.115139_bb0205","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3109\/10428194.2015.1034701","article-title":"NOD\/SCID IL2Rgamma-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines","volume":"56","author":"Verner","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.taap.2020.115139_bb0210","series-title":"Dendrimer Chemistry: Concepts, Syntheses, Properties, Applications, Dendrimer Chemistry: Concepts, Syntheses, Properties, Applications","author":"V\u00f6gtle","year":"2009"},{"key":"10.1016\/j.taap.2020.115139_bb0215","doi-asserted-by":"crossref","first-page":"19330","DOI":"10.3390\/molecules201019330","article-title":"Poly(propylene imine) dendrimers and amoxicillin as dual-action antibacterial agents","volume":"20","author":"Wronska","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.taap.2020.115139_bb0220","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1080\/10543401003618983","article-title":"Statistical inference for tumor growth inhibition T\/C ratio","volume":"20","author":"Wu","year":"2010","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.taap.2020.115139_bb0225","first-page":"887","article-title":"The influence of bendamustine used either alone or in combination with purine nucleoside analogues on the viability and apoptosis of chronic lymphocytic leukemia cells in culture in vitro","volume":"40","author":"Zaborowska","year":"2009","journal-title":"Acta Haematol. Pol."},{"key":"10.1016\/j.taap.2020.115139_bb0230","doi-asserted-by":"crossref","DOI":"10.1002\/jbm.a.33196","article-title":"In vivo toxicity of poly(propyleneimine) dendrimers","volume":"99A","author":"Ziemba","year":"2011","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"10.1016\/j.taap.2020.115139_bb0235","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/jbm.a.34222","article-title":"Influence of fourth generation poly(propyleneimine) Dendrimers on blood cells","volume":"100A","author":"Ziemba","year":"2012","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"10.1016\/j.taap.2020.115139_bb0240","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/bip.22056","article-title":"Genotoxicity of poly(propylene imine) dendrimers","volume":"97","author":"Ziemba","year":"2012","journal-title":"Biopolymers"},{"key":"10.1016\/j.taap.2020.115139_bb0245","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ijpharm.2013.12.011","article-title":"Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: considering their contrary potential as biocompatible entity and drug molecule in cancer","volume":"461","author":"Ziemba","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.taap.2020.115139_bb0250","article-title":"Anti-tumour activity of Glycodendrimer nanoparticles in a subcutaneous MEC-1 Xenograft model of human chronic lymphocytic Leukemia","volume":"19","author":"Ziemba","year":"2019","journal-title":"Anti Cancer Agents Med. Chem."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20302659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20302659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:51:15Z","timestamp":1758574275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X20302659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":50,"alternative-id":["S0041008X20302659"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2020.115139","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2020.115139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115139"}}